Low Expression of TOX Predicts Poor Prognosis of Patients with Breast Cancer in the Real World: A Retrospective Study

Overview

Journal Heliyon

Specialty Social Sciences

Date 2025 Jan 6

PMID 39758401

Authors

Chunlei Tan

Danping Wu

Xiaotian Yang

Shiyuan Zhang

Shuqiang Liu

Boqian Yu

Xiao Yu

Yuting Xiu

Yuanxi Huang

Affiliations

Soon will be listed here.

Abstract

Background: TOX is a transcription factor that is implicated in the regulation of T cell exhaustion in tumors. TOX has been proven to have prognostic value in some malignant tumors. We aim to analyze the expression of TOX in breast cancer patients, and the association between TOX and prognostic significance in patients with breast cancer.

Methods: 313 breast cancer patients were enrolled into this study. The expression of TOX was determined by immunohistochemistry assay. Survival curves were performed by Kaplan-Meier and log-rank test. The potential independent factors were assessed by Cox regression analyses. Nomogram models, calibration curve, decision curve analyses were applied to analyze the clinical utility of predictive models.

Results: According to semi-quantitative scoring, 129 patients were classified into low group, and 184 patients were classified into high group. Patients with high expression of TOX had a longer survival than those with low expression of TOX (DFS: 71.70 vs. 64.05 months, χ = 11.6300, P = 0.00065; OS: 81.03 vs. 73.72 months, χ = 11.4200, P = 0.00073). Based on Cox regression analyses, multivariate analysis indicated that TOX was the potential prognostic factor for both DFS (HR: 0.412, 95 % CI: 0.248-0.684, P = 0.001) and OS (HR: 0.395, 95 % CI: 0.237-0.660, P < 0.0001). Calibration curve analysis showed that the predicted line was well-matched with baseline regarding postoperative 1-, 3-, and 5-year survival rate.

Conclusions: The expression of TOX is a potential prognostic factor, and can be a promising biomarker for predicting survival in breast cancer patients.

References

Scott A, Dundar F, Zumbo P, Chandran S, Klebanoff C, Shakiba M . TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019; 571(7764):270-274. PMC: 7698992. DOI: 10.1038/s41586-019-1324-y. View

Chen Y, Feng Z, Kuang X, Zhao P, Chen B, Fang Q . Increased lactate in AML blasts upregulates TOX expression, leading to exhaustion of CD8 cytolytic T cells. Am J Cancer Res. 2021; 11(11):5726-5742. PMC: 8640829. View

Jones J, Chin S, Wong-Taylor L, Leaford D, Ponder B, Caldas C . TOX3 mutations in breast cancer. PLoS One. 2013; 8(9):e74102. PMC: 3777980. DOI: 10.1371/journal.pone.0074102. View

Han H, Jeong S, Kim H, Kim H, Kim A, Kwon M . TOX-expressing terminally exhausted tumor-infiltrating CD8 T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Lett. 2020; 499:137-147. DOI: 10.1016/j.canlet.2020.11.035. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Liang Y, Zhang H, Song X, Yang Q . Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2019; 60:14-27. DOI: 10.1016/j.semcancer.2019.08.012. View

Han Y, Zhang J, Zheng Y, Huo D, Olopade O . Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer. PLoS One. 2016; 11(11):e0165559. PMC: 5091860. DOI: 10.1371/journal.pone.0165559. View

Glajcar A, Szpor J, Hodorowicz-Zaniewska D, Tyrak K, Okon K . The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status. Virchows Arch. 2019; 475(1):13-23. PMC: 6611750. DOI: 10.1007/s00428-019-02568-y. View

Yao C, Sun H, Lacey N, Ji Y, Moseman E, Shih H . Single-cell RNA-seq reveals TOX as a key regulator of CD8 T cell persistence in chronic infection. Nat Immunol. 2019; 20(7):890-901. PMC: 6588409. DOI: 10.1038/s41590-019-0403-4. View

10.

Oladejo M, Paulishak W, Wood L . Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Semin Cancer Biol. 2022; 88:81-95. DOI: 10.1016/j.semcancer.2022.12.003. View

11.

Beltra J, Abdel-Hakeem M, Manne S, Zhang Z, Huang H, Kurachi M . Stat5 opposes the transcription factor Tox and rewires exhausted CD8 T cells toward durable effector-like states during chronic antigen exposure. Immunity. 2023; 56(12):2699-2718.e11. PMC: 10752292. DOI: 10.1016/j.immuni.2023.11.005. View

12.

Gajewski T, Schreiber H, Fu Y . Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10):1014-22. PMC: 4118725. DOI: 10.1038/ni.2703. View

13.

Ciriello G, Gatza M, Beck A, Wilkerson M, Rhie S, Pastore A . Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015; 163(2):506-19. PMC: 4603750. DOI: 10.1016/j.cell.2015.09.033. View

14.

Guo L, Li X, Liu R, Chen Y, Ren C, Du S . TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma. Cancer Med. 2020; 9(18):6694-6709. PMC: 7520261. DOI: 10.1002/cam4.3324. View

15.

Zhang Q, Gao C, Shao J, Wang Z . TIGIT-related transcriptome profile and its association with tumor immune microenvironment in breast cancer. Biosci Rep. 2021; 41(3). PMC: 7990089. DOI: 10.1042/BSR20204340. View

16.

Tessema M, Yingling C, Grimes M, Thomas C, Liu Y, Leng S . Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers. PLoS One. 2012; 7(4):e34850. PMC: 3319602. DOI: 10.1371/journal.pone.0034850. View

17.

Li S, Yang S, Hong Y . Higher thymocyte selection-associated high mobility group box (TOX) expression predicts poor prognosis in patients with ovarian cancer. BMC Cancer. 2022; 22(1):1216. PMC: 9701062. DOI: 10.1186/s12885-022-10336-6. View

18.

Gaikwad S, Agrawal M, Kaushik I, Ramachandran S, Srivastava S . Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. Semin Cancer Biol. 2022; 86(Pt 3):137-150. DOI: 10.1016/j.semcancer.2022.03.014. View

19.

Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim H, Roelli P . TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019; 571(7764):265-269. DOI: 10.1038/s41586-019-1326-9. View

20.

Page N, Lemeille S, Vincenti I, Klimek B, Mariotte A, Wagner I . Persistence of self-reactive CD8+ T cells in the CNS requires TOX-dependent chromatin remodeling. Nat Commun. 2021; 12(1):1009. PMC: 7881115. DOI: 10.1038/s41467-021-21109-3. View